Executive Summary
- Precision Optics posted Q4 2024 results with revenue of 4.72 million, up 9.1% year-over-year but down 10.0% quarter-over-quarter, signaling a modest top-line recovery offset by margin compression in a tight cost environment. Gross profit of 1.02 million yielded a gross margin of 21.72%, a meaningful deterioration from Q4 2023 (about 35.0%), underscoring pricing/mix pressure or elevated cost of goods sold.
- Operating performance remained negative, with operating income of -1.36 million and EBITDA of -1.30 million, resulting in a net loss of -1.41 million and EPS of -0.23 for the quarter. Cash flow from operations was -0.98 million and free cash flow was -0.99 million, highlighting ongoing cash burn despite revenue strength. The company ended the period with approximately 0.405 million in cash, total debt around 3.43 million, and net debt of roughly 3.03 million, signaling near-term liquidity considerations absent a capital action or material profitability improvement.
- The balance sheet shows a solid equity base (approx. 10.07 million) and sizable goodwill/intangible assets (Goodwill 8.82 million; Intangibles 0.29 million; total noncurrent assets ~9.79 million), implying exposure to impairment risk if profitability does not improve. Near-term catalysts will likely hinge on cost-control, mix optimization toward higher-margin offerings, and potential external funding to sustain operations. Management commentary is not provided in the transcript data available for this analysis, limiting direct insight into forward-looking guidance.
Key Performance Indicators
QoQ: -44.88% | YoY:-30.01%
QoQ: -424.64% | YoY:-234.66%
QoQ: -345.07% | YoY:-203.85%
QoQ: -340.61% | YoY:-200.26%
Key Insights
Revenue: 4,716,227 (Q4 2024); YoY +9.14%, QoQ -10.04%
Gross Profit: 1,024,453; Gross Margin 21.72% (vs. ~35% in Q4 2023)
Operating Income: -1,356,351; Operating Margin -28.76%
EBITDA: -1,300,555; EBITDA Margin ~ -27.58%
Net Income: -1,411,105; Net Margin -29.92%
EPS (diluted): -0.23; Shares (avg): 6,068,329
Cash Flow: Operating -976,014; Free Cash Flow -987,819; Net Change in Cash -519,789
Balance Sheet: Cash & equivalents 405,278; Total Assets 16,912,574; Total Liabilities 6,844,786; Total ...
Financial Highlights
Revenue: 4,716,227 (Q4 2024); YoY +9.14%, QoQ -10.04%
Gross Profit: 1,024,453; Gross Margin 21.72% (vs. ~35% in Q4 2023)
Operating Income: -1,356,351; Operating Margin -28.76%
EBITDA: -1,300,555; EBITDA Margin ~ -27.58%
Net Income: -1,411,105; Net Margin -29.92%
EPS (diluted): -0.23; Shares (avg): 6,068,329
Cash Flow: Operating -976,014; Free Cash Flow -987,819; Net Change in Cash -519,789
Balance Sheet: Cash & equivalents 405,278; Total Assets 16,912,574; Total Liabilities 6,844,786; Total Equity 10,067,788
Liquidity & Leverage: Current Ratio 1.451; Quick Ratio 0.866; Cash Ratio 0.0826; Debt 3,434,461; Net Debt 3,029,183; Debt/Equity 0.34; Interest Coverage (reported) 25.62x
Efficiency: DSO 51.9 days; DIO negative -15.63 days; Receivables Turnover 1.73x; Inventory Turnover -5.76x; Asset Turnover 0.364; Enterprise Value Multiple 9.78x
Valuation: Price-to-Book 1.18x; Price-to-Sales 1.93x; Price-to-Operating Cash Flows negative; EV/EBITDA not provided precisely due to negative EBITDA
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
4.72M |
9.14% |
-10.04% |
| Gross Profit |
1.02M |
-30.01% |
-44.88% |
| Operating Income |
-1.36M |
-234.66% |
-424.64% |
| Net Income |
-1.41M |
-203.85% |
-345.07% |
| EPS |
-0.23 |
-200.26% |
-340.61% |
Key Financial Ratios
operatingProfitMargin
20.5%
operatingCashFlowPerShare
$-0.42
freeCashFlowPerShare
$-0.48
Management Commentary
- No earnings call transcript was provided in the supplied data; as a result, there are no management quotes or thematic highlights to group by strategy, operations, or market conditions. If a transcript becomes available, benefits would include tying quantitative results to management commentary on margin initiatives, product mix, and liquidity plans.
Forward Guidance
- There is no explicit forward guidance in the provided data for QQ4 2024. Given the ongoing net losses and operating cash burn, the near-term outlook hinges on: (i) cost structure optimization (R&D vs. SG&A alignment), (ii) revenue mix and growth in higher-margin optical imaging products, and (iii) access to additional liquidity or refinancing to bridge operating losses. Investors should monitor: how the company advances profitability (gross margin recovery, scaling of high-margin offerings), working capital management (receivables/payables dynamics), and any announced capital actions (debt revision, equity issuance, or strategic partnerships). Potential catalysts could include commercial traction in endoscopes/3D endoscopes, new customer contracts, or licensing arrangements that improve cash flow. In the absence of a clear guidance path, the investment thesis remains contingent on successful cost control and capital strategy to sustain a cash burn at the current scale.